One of the main challenges in administering G-CSF is determining the optimal dosing regimen to maximize benefit while minimizing adverse effects. The timing of administration relative to chemotherapy cycles is critical to achieving the desired therapeutic outcomes. Additionally, the potential for antibody formation against G-CSF, which can reduce its efficacy, is an important consideration.
